Electronic mindfulness-based music therapy for patients receiving stem cell transplantation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study uses two eHealth therapies—eMBMT and eMM—to support adults with hematologic malignancies who are planned for a stem cell transplant. Participants will engage in mindfulness and music-based interventions delivered electronically while undergoing treatment. The goal is to see if these interventions improve health-related quality of life, symptom burden, and disease activity compared with standard care. The study is led by the University of Miami with NCI collaboration and is conducted at the University of Miami in Florida.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥ 18 years of age
* have a primary diagnosis of a hematologic malignancy (e.g., myelodysplastic syndrome \[MDS\], acute myeloid leukemia \[AML\], acute lymphoblastic leukemia \[ALL\], or non Hodgkin's Lymphoma \[NHL\])
* have a treatment plan for a hematopoietic stem cell transplant
* Speak English or Spanish

Exclusion Criteria:

* history of severe psychiatric illness (e.g., psychosis, active suicidality, inpatient treatment in the past 12 months)
* severe cognitive impairment (per the short portable mental status questionnaire)
* hearing impairment
* active alcohol or substance dependence within the past six months
* participated in the prior pilot MBMT R61 phase
* participated in music therapy or mindfulness programs in the past six months

Where it's running

• University of Miami
  Miami, Florida, United States Recruiting

Study contacts

• Principal investigator: Frank J Penedo, PhD — University of Miami
• Study coordinator: Frank J Penedo, PhD
• Email: fpenedo@miami.edu
• Phone: (305) 284-4290

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Orca-T after reduced-intensity or nonmyeloablative conditioning for adults with AML or MDS

  This trial will test whether Orca-T, a donor-derived stem cell and T-cell therapy, is safe and helps adults with acute myeloid leukemia or myelodysplastic syndrome who are receiving reduced-intensity or nonmyeloablative allogeneic stem cell transplants.

  Recruiting at 6 sites Phase 2 Orca Biosystems, Inc. · Los Angeles, California and 5 other locations · NCT07216443

• Registry for patients with myelodysplastic syndromes and therapy-related acute myeloid leukemia

  This study is collecting health information from adults with myelodysplastic syndromes and therapy-related acute myeloid leukemia to better understand these conditions and improve patient care.

  Recruiting Groupe Francophone des Myelodysplasies · Rouen · NCT06956755

• Testing BH-30236 for relapsed or refractory acute myelogenous leukemia and higher-risk myelodysplastic syndrome

  This study is testing a new drug called BH-30236 to see if it can help adults with relapsed or hard-to-treat acute myelogenous leukemia or higher-risk myelodysplastic syndrome.

  Recruiting at 13 sites Phase 1 BlossomHill Therapeutics · Duarte, California and 12 other locations · NCT06501196

• Depleting specific immune cells in stem cell transplants for blood cancers

  This study is testing if removing certain immune cells during stem cell transplants can help children and young adults with blood cancers have better outcomes and fewer complications.

  Recruiting Phase 2 University of Florida · Gainesville, Florida · NCT05800210

• Testing Enzomenib for patients with relapsed or refractory acute leukemia

  This study is testing a new drug called Enzomenib to see if it can help adults with relapsed or hard-to-treat acute leukemia feel better.

  Recruiting at 80 sites Phase 1/2 Sumitomo Pharma America, Inc. · Newport Beach, California and 103 other locations · NCT04988555

• Fecal Microbiota Transplantation to Prevent Complications After Stem Cell Transplantation

  This study is testing whether giving a special stool treatment can help prevent complications like Graft-versus-Host Disease in patients receiving stem cell transplants for blood cancers.

  Recruiting at 3 sites Phase 2 University Hospital, Clermont-Ferrand · Amiens and 19 other locations · NCT04935684

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.